(Q37639711)

English

Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy (English)

1 reference

Europe PubMed Central

21 August 2017

molecular chaperones

0 references

1 reference

based on heuristic

inferred from title

Matteo Landriscina

1

1 reference

Europe PubMed Central

21 August 2017

Franca Esposito

4

1 reference

Europe PubMed Central

21 August 2017

Maria Rosaria Amoroso

object named as

Maria Rosaria Amoroso

2

0 references

author name string

Annamaria Piscazzi

3

1 reference

Europe PubMed Central

21 August 2017

language of work or name

0 references

publication date

25 November 2009

1 reference

Europe PubMed Central

21 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

21 August 2017

117

1 reference

Europe PubMed Central

21 August 2017

2

1 reference

Europe PubMed Central

21 August 2017

177-182

1 reference

Europe PubMed Central

21 August 2017

Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Hsp90: a specialized but essential protein-folding tool

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Small stress proteins: novel negative modulators of apoptosis induced independently of reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Specific stimulation of human apurinic/apyrimidinic endonuclease by heat shock protein 70.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

AROS-29 is involved in adaptive response to oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Generation of prooxidant conditions in intact cells to induce modifications of cell cycle regulatory proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Adaptation to oxidative stress, chemoresistance, and cell survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Critical evaluation of current treatments in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Hsp90: the vulnerable chaperone

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Rational design of shepherdin, a novel anticancer agent.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

The biology of ovarian cancer: new opportunities for translation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces or

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.10.078

7 January 2021

Identifiers

10.1016/J.YGYNO.2009.10.078

1 reference

Europe PubMed Central

21 August 2017

1 reference

Europe PubMed Central

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37639711&oldid=1717207019"